Abstract: An art investment estimation system is provided that is updated to include a first sale price and date, and a second sale price and date of a plurality of repeat sale pairs of a plurality of works of art associated with an artist. The system determines one or more investment value variables derived from the first sale price and associated first sale date and the second sale price and associated second sale date for the plurality of repeat sale pairs of the plurality of works of art. The system receives, at a graphical user interface (GUI), input from a user designating weights for the investment value variables for an artist. The system determines, from the designated weights and the investment value variables, an artist investment potential value for the artist and, at the GUI, displays to the user the artist investment potential value.

Abstract: An art investment estimation system is provided that is updated to include a first sale price and date, and a second sale price and date of a plurality of repeat sale pairs of a plurality of works of art associated with an artist. The system determines one or more investment value variables derived from the first sale price and associated first sale date and the second sale price and associated second sale date for the plurality of repeat sale pairs of the plurality of works of art. The system receives, at a graphical user interface (GUI), input from a user designating weights for the investment value variables for an artist. The system determines, from the designated weights and the investment value variables, an artist investment potential value for the artist and, at the GUI, displays to the user the artist investment potential value.

Abstract: An art investment estimation system is provided that is updated to include a first sale price and date, and a second sale price and date of a plurality of repeat sale pairs of a plurality of works of art associated with an artist. The system determines one or more investment value variables derived from the first sale price and associated first sale date and the second sale price and associated second sale date for the plurality of repeat sale pairs of the plurality of works of art. The system receives, at a graphical user interface (GUI), input from a user designating weights for the investment value variables for an artist. The system determines, from the designated weights and the investment value variables, an artist investment potential value for the artist and, at the GUI, displays to the user the artist investment potential value.

Abstract: The invention relates to a modified VWF molecule for use in the treatment of a blood coagulation disorder.

Abstract: A transition adapter for routing a first optical cable into a plurality of optical cables of the present disclosure has a main body. In addition, the transition adapter has a first channel within the main body and configured for receiving the first optical cable, a second channel, the first channel open to the second channel, the second channel within the main body and configured for receiving a second optical cable, which is a first portion of the first optical cable, the second channel terminating with a first opening from which the second optical cable extends, and a third channel, the first channel open to the third channel, the third channel within the main body and configured for receiving a third optical cable, which is a second portion of the first optical cable, the third channel terminating with a second opening from which the third optical cable extends.

Abstract: An art investment estimation system is provided that is updated to include a first sale price and date, and a second sale price and date of a plurality of repeat sale pairs of a plurality of works of art associated with an artist. The system determines one or more investment value variables derived from the first sale price and associated first sale date and the second sale price and associated second sale date for the plurality of repeat sale pairs of the plurality of works of art. The system receives, at a graphical user interface (GUI), input from a user designating weights for the investment value variables for an artist. The system determines, from the designated weights and the investment value variables, an artist investment potential value for the artist and, at the GUI, displays to the user the artist investment potential value.

Abstract: The instant invention provides a method to reduce adverse events caused by a pharmaceutical preparation derived from a plasma fraction wherein the method comprises contacting the plasma fraction with heparin or a heparin-like substance thereby reducing the activity of at least one activated serine protease per ml of the plasma fraction.

Abstract: A transition adapter for routing a first optical cable into a plurality of optical cables of the present disclosure has a main body. In addition, the transition adapter has a first channel within the main body and configured for receiving the first optical cable, a second channel, the first channel open to the second channel, the second channel within the main body and configured for receiving a second optical cable, which is a first portion of the first optical cable, the second channel terminating with a first opening from which the second optical cable extends, and a third channel, the first channel open to the third channel, the third channel within the main body and configured for receiving a third optical cable, which is a second portion of the first optical cable, the third channel terminating with a second opening from which the third optical cable extends.

Abstract: The invention relates to compositions comprising an isolated sugar for use in the treatment of von Willebrand disease and/or hemophilia A, wherein the sugar is an accessible sugar residue derived from ABO(H) blood group antigen.

Abstract: The invention relates to a modified VWF molecule for use in the treatment of a blood coagulation disorder.

Abstract: The invention relates to a compound, preferably an antibody, capable of binding to the receptor protein CLEC10A for use in the treatment of a blood coagulation disorder.

Abstract: The invention relates to compositions comprising an isolated sugar for use in the treatment of von Willebrand disease and/or hemophilia A, wherein the sugar is an accessible sugar residue derived from ABO(H) blood group antigen.

Abstract: The invention relates to compositions comprising an isolated sugar for use in the treatment of von Willebrand disease and/or hemophilia A, wherein the sugar is an accessible sugar residue derived from ABO(H) blood group antigen.

Abstract: The invention provides a computer implemented method for constructing a patient-specific evidence-informed case rate (ECR) for an episode of medical care spanning a defined period of time for a particular payer-provider-patient triad to create a patient-specific, severity adjusted prospective budget for the patient. ECR Analytics is a tool that constructs episodes of care using administrative claims data, both medical and pharmacy. It calculates the cost of care of patient-specific episodes by assigning relevant services to each episode and further distinguishing those services as typical or routine versus those associated with a complication. The episodes calculated within ECR Analytics can be attributed to specific providers, risk adjusted for performance measurement, and can also be used to construct prospective budgets for payment purposes, such as episode of care payment or reference pricing.

Abstract: The instant invention provides a method to reduce adverse events caused by a pharmaceutical preparation derived from a plasma fraction said plasma fraction comprising antithrombin III wherein the method comprises contacting the plasma fraction with heparin or a heparin-like substance thereby reducing the activity of at least one activated serine protease per ml of the plasma fraction.

Abstract: The invention relates to compositions comprising an isolated sugar for use in the treatment of von Willebrand disease and/or hemophilia A, wherein the sugar is an accessible sugar residue derived from ABO(H) blood group antigen.

Abstract: The Episode Builder according to exemplary embodiments of the present invention is a web-based computer application and its associated architecture that allows health care professionals to define and describe episodes of care. The Episode Builder provides a unique tool for these purposes. Using industry-standard code sets, the Episode Builder describes and defines an episode of care so that the health care professional can create and modify episodes for a variety of purposes. The three main components of the Episode Builder are a configurable and extensive code set management system, a suite of display panels that define the episodes themselves based upon the code sets, and a means to export the episode definition tables thus created to be used as inputs into an analytic program or a claims adjudication engine.

Abstract: The instant invention provides a method to reduce adverse events caused by a pharmaceutical preparation derived from a plasma fraction wherein the method comprises contacting the plasma fraction with heparin or a heparin-like substance thereby reducing the activity of at least one activated serine proteaseper ml of the plasma fraction.

Abstract: A medical implant device includes a shaft, an expandable member coupled to the distal end portion of the shaft, a sleeve and a detachment mechanism. The expandable member is configured to move between a collapsed configuration and an expanded configuration, and can be used to deliver a medicament, a therapeutic substance and/or a structural member into the body. The sleeve is coupled to the distal end portion of the shaft, and is configured to move relative to the shaft between a first position and a second position. The sleeve is configured to be disposed about the expandable member when in the first position and disposed apart from the expandable member when in the second position. The detachment mechanism is coupled to the distal end portion of the shaft, and is configured to detach the expandable member from the shaft when the sleeve is in the second position.

Abstract: An electrode assembly for use in combination with an electrosurgical instrument having opposing end effectors and a handle for effecting movement of the end effectors relative to one another. The electrode assembly includes a housing having one portion which is removably engageable with the electrosurgical instrument and a pair of electrodes each having an electrically conductive sealing surface and an insulating substrate. The electrodes are removably engageable with the end effectors of the electrosurgical instrument such that the electrodes reside in opposing relation relative to one another. The dimensions of the insulating substrate are different from the dimensions of the electrically conductive sealing surface to reduce thermal spread to adjacent tissue structures.